Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
November 2025
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy
Porvair Sciences expands range of black microplates
, /in Product News /by 3wmediaPorvair Sciences has expanded its range of high quality, black microplates that minimise sample degradation by exposure to light, even over long storage periods.
Available in a choice of 48-, 96- and 384-well formats – the black plates are precisely manufactured to applicable ANSI / SLAS dimensions ensuring complete compatibility with almost all readers and automated equipment. Manufactured from polypropylene, the range of black microplates offer excellent heat and solvent resistant qualities. Using only ultra-pure grade polymer means that each black plate has near zero leachates ensuring long-term sample integrity. The black plates are supplied RNase / DNase free meaning they can be used to store the most sensitive biological samples. To prevent evaporation, hydration of DMSO solutions and to completely eliminate light from samples – Porvair Sciences additionally offers a selection of Absorb Max light blocking sealing films that may be applied to the top of the black plates. A split backing and edge cut-outs make positioning and applying the sealing film quick and simple. The light-blocking and absorbing properties of Porvair Sciences black microplates, used in conjunction with Absorb Max sealing films, provides a perfect combination for protecting light-sensitive assays or samples during storage.
For more information, visit: www.microplates.com/solid-bottom
Read more
GE Healthcare Life Sciences releases software for cell therapy workflow
, /in Product News /by 3wmediaGE Healthcare Life Sciences continues to build out its flexible solutions across the cell therapy workflow with the commercial availability of SpinOculation C-Pro Protocol Software. Part of the Sepax™ C-Pro Cell Processing System, the software closes and automates the cell transduction step. When used in combination with the Sepax C-Pro instrument and CT-60.1 single-use kit, the software enables users to choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences, said: “Cell therapy manufacturing is complex and requires advanced technologies.
The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next generation therapeutics.” Additionally, the SpinOculation C-Pro Protocol helps users:
The SpinOculation C-Pro application software is available worldwide.
Read more
Colourful, stretchable silicon lids securely cover open beakers and bottles
, /in Product News /by 3wmediaUsing aluminium foil or plastic wrap to cap beakers and flasks has always been a quick fix with questionable effectiveness. In an effort to provide lids that are safe and easy to use, DWK Life Sciences, a leading manufacturer of precision labware, has developed KIMBLE® Silicon Lids that stretch and conform to beaker tops for a tight and secure seal.
Available in three sizes and three colours, KIMBLE Silicon Lids easily conform to fit on beakers, flasks, bottles and cylinders. The stretchy silicone material creates a seal on spouts, beaded tops or threaded necks on glass or plastic vessels. The lids are resistant to heat and chemicals and designed with tabs, so they are easy to put on or take off, even when wearing gloves. Dishwasher-safe and reusable, the lids are a sustainable solution for environmentally conscious labs. The lids come in bright colours for easy colour coding.
“We’ve been surprised with the popularity of these unique covers – we knew they were safe, secure and provided a better seal for different laboratory containers, but we were just as happy to see how scientists liked their appearance – they’re using the lids to improve the appearance of the labs by replacing makeshift foil caps and stoppers with bright colours,” said Rick Schwartz, Senior Vice President of Marketing and Sales at DWK Life Sciences. “There is currently no other lab grade product available that remotely resembles our lids.”
KIMBLE Silicon Lids have stretchable diameters; small 43 to 61 mm diameter, medium 64 to 76 mm diameter, and large lids are 84 to 116 mm diameter. Colour choices include pink, green and blue. Lids easily accommodate most 50 ml beakers up to 800 ml beakers. The silicon is resistant to most chemicals and withstands heat with a usable temperature range of 40°C to 180°C. KIMBLE Silicon Lids are sold individually or in packages of 3 containing a small, medium and large sized lid in each package.
For more information, visit: https://dwk.com/colorsplash
Read more
Ziath’s 2D-barcoded cryogenic tubes set a new standard
, /in Product News /by 3wmediaThe Ziath range of CryzoTraq™ 2D-barcoded cryogenic tubes set a new standard for cryogenic storage of biological specimens at temperatures as low as -196°C.
Worldwide biobanks and biorepositories support many types of life science research including Genomics and Personalized Medicine. To ensure the integrity and viability of specimens stored in these sample storage facilities over long periods of time, the specimens are placed in a sterile storage tubes and immersed in vapor phase Liquid Nitrogen. Leak-free cryogenic tubes are therefore of utmost importance to ensure sample integrity. Produced using an innovative 2-stage injection moulding process the caps on CryzoTraq tubes deliver outstanding leak resistance. This high integrity closure on CryzoTraq tubes ensures that the sample cannot leak out and conversely that no contaminants can enter the tube. This is vitally important because if the specimen is contaminated, it is rendered useless for further research.
To ensure full sample traceability, all CryzoTraq tubes have a 2D datamatrix barcode inserted in the base of the tube. The insert is secured in place by the use of ultrasound to weld it into place. During this manufacturing process, a linear barcode is printed onto the side of the tube first, and the 2D code is automatically generated from the linear barcode therefore ensuring the two barcodes will always be the same with no errors.
Available in 2 ml and 5 ml volumes, CryzoTraq tubes are certified free from DNA, DNase, RNase, pyrogens and ATP. Each lot is sterilized with electron beam radiation. CryzoTraq tubes are manufactured from medical grade polypropylene and the caps from medical grade polyethylene.
To enable fast and precise decoding of the 2D-barcodes on CryzoTraq tubes, Ziath offers its high performance DataPaq™ Multirack and Cube scanners.
For more information, visit: www.ziath.com/index.php/products/tubes/ cryzotraq-tubes-and-racks
Read more
Molecular diagnostics platform for fast and point-of-care disease diagnosis
, /in Corona News, Product News /by 3wmediaMolecular diagnostics is known to have superior advantages for routine detection of infectious diseases and now has a very prominent place in clinical laboratories. Based on the principle of DNA/RNA amplification, molecular diagnostic techniques help in early diagnosis of infectious diseases, providing the added edge of excellent sensitivity and specificity. However, this technique has, thus far, been limited to centralized laboratories due to dependency on complex and expensive infrastructure, highly skilled manpower, special storage conditions and a need for batch testing. This results in high turn-around time and poses major logistics challenges, such as sample degradation, contamination, report delays, etc.
Molbio Diagnostics Pvt Ltd has developed and commercialized Truelab™, a commercial point-of-care (POC) molecular diagnostics platform that uses PCR technology with Truenat test chips. Truenat™ disease-specific test chips are available for the diagnosis of 22 infectious diseases (such as TB, H1N1, dengue, HIV, hepatitis, etc) and an additional 43 diseases (such as coronavirus, MERS, etc) are in the pipeline.
The Truelab™ platform, a global first, is a compact, battery-operated system, with single testing capability and provides sample-toresult times within 1 hour. Hence, it enables same-day reporting and initiation of evidencebased treatment for the patient. Doctors benefit from this technology by having a definitive diagnosis, early in the infection cycle, without patients/samples having to travel extensively to centralized facilities.
The Truenat™ assay is rapid and affordable with minimal infrastructure requirements. Thus, placing the Truelab™ multi-disease detection system in the most remote settings will enable mass access to advanced molecular testing for people of all socio-economic backgrounds, across the globe. The device has real-time data transfer capability (through SMS/email) for immediate reporting of results in emergency cases. Additionally, a cloud-based centralized data monitoring and surveillance network can be created and linked to all devices in a region. Complete data from tests performed can be accessed, analysed and recorded in real time. Such same-day reporting of results will strengthen the healthcare systems across countries by improving effectiveness of providing treatment and quarantining of patients, thus controlling spread of communicable diseases. The device is ideal for places that do not get regular electricity, and will work well even in primary healthcare centres, unlike other devices that require uninterrupted power supply, elaborate infrastructure and air-conditioning.
Molbio’s technology has been approved by the Indian Council of Medical Research in 2018, after 3 years of validation study across various sites in India. Internationally, the World Health Organization (WHO), after conducting a multicountry study, has released a rapid communication in January 2020 endorsing Truenat™ as an initial diagnostic test of Mycobacterium tuberculosis (MTB) and MTB-RIF (MTB rifampicin resistance) in view of its high diagnostic accuracy. The WHO has further endorsed Truenat™ for diagnosis of TB as a replacement of the less sensitive sputum smear microscopy. The performance of Truenat™ shows comparable accuracy with other WHO approved tests such as Genexpert, TB-LAMP® and line probe assay. Truenat™ will help in decentralizing and democratizing access to high quality diagnostics to millions of patients suffering from TB and other infectious diseases even at peripheral and remote settings.
At present, Truelab™ devices are installed in over 500 private laboratories, 350 government primary health centres in India and in 27 countries around the globe, extending across the continents of Asia, Africa, Europe and South America. WHO endorsement will further enable the product to be commercialized across more than 150 countries.
Truelab™ is patented across over 100 countries which enables the transition from presumptive to efficient, real-time and precise diagnosis of multiple diseases at reasonable price even in primary healthcare centres and smaller diagnostics labs, which can now deliver high-end molecular diagnostic tests.
Molbio Diagnostics is driven by the urgent need to provide world-class medical devices to enable better medicine through precise, faster, cost effective diagnosis and envisions to be a leading global player in the POC diagnostics segment by continuing to innovate and bring new technologies for social betterment.
In addition, given the current coronavirus pandemic, Molbio is pleased to announce that the Truenat™ Beta-CoV POC RT-PCR test is currently being validated through a regulatory process and is expected to be commercially available in the next couple of weeks. This rapid, portable, POC solution will enable molecular testing for COVID-19 to be performed even at the community level and will provide results within 1 hour from sampling.
Read more
Exosomics implements PRODUCT NanoFCM’s NanoAnalyzer to provide advanced extracellular vesicles-focused research services
, /in Product News /by 3wmediaRead more
Randox unveils new coronavirus test at Medlab Middle East 2020
, /in Product News /by 3wmediaA ground-breaking test for the potentially fatal 2019-nCoV strain of coronavirus, is in the final stages of development at global health diagnostics company Randox Laboratories. The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate SARS-COV-2 testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms. The new enhanced Biochip will therefore allow clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented; “Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of 2019-nCoV, and therefore neglect to differentiate between this strain and other respiratory infections. Whilst we’re very quickly developing an efficient novel test for this new strain of coronavirus, we are therefore also working on an extended Viral Respiratory Infection Array that will test simultaneously for 2019-nCoV and a range of other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.” The test will be available for the Point of Care analyser, the Vivalytic, within 3 hours, and within 5 hours on the Randox Evidence Investigator. Benefits of the new Randox SARS-COV-2 test
Read more
Compact random access analyser
, /in Product News /by 3wmediaThe RA Analyzer 10 is a compact random access device which provides fully automated processing of chemiluminescence immunoassays (ChLIA) for autoimmune and infection diagnostics as well as antigen detection. It is ideal for use in small- to medium-sized laboratories, or to complement high-throughput-devices in large laboratories.
The device allows continuous loading, also as part of a laboratory track system, ensuring that every sample is processed with minimal effort as a single determination. Up to 85 results can be obtained per hour. EUROIMMUN ChLIA technology offers short reaction times, with first results in just 25 minutes. Test- and lot-specific information, including stored standard curves, is imported by means of RFID codes, enabling error-free and convenient loading, along with efficient and secure test evaluation. Automatic identification of samples and reagents by means of barcodes ensures complete traceability. The system offers preferential processing of emergency samples (STAT), giving laboratories unparalleled flexibility in their laboratory routine.
New CE-marked EUROIMMUN ChLIA for use on the RA Analyzer 10 are available for detection of antibodies against Borrelia (IgG, IgM) Epstein-Barr virus (EBV-CA IgG, IgM; EBNA IgG), proteinase 3 (PR3, IgG) and phospholipase A2 receptor (PLA2R, IgG). Further ChLIA for detection of antibodies against tissue transglutaminase (tTG, IgA), CCP (IgG), myeloperoxidase (MPO, IgG), parvovirus B19 (IgG, IgM), HSV-1 (IgG) and HSV-2 (IgG), as well as calprotectin and biomarkers in Alzheimer’s disease will be available soon. Assays for many other parameters are under development.
Read more
Multiplex assay for 10 STI’s receives CE mark
, /in Product News /by 3wmediaCE marking has been granted to one of the most comprehensive cartridge-based STI tests. The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology. Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling. Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented; “Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”
The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size. Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.
Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said: “We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”
Read more
DiaSys assay for cardiovascular disease, stroke Lp-PLA2 biomarker
, /in Product News /by 3wmediaLp-PLA2 (Lipoprotein-associated phospholipase A2) is an inflammatory enzyme expressed in atherosclerotic plaques. It is determined as an additional and vascular specific biomarker to predict risk for cardiovascular disease and stroke.
Guidelines from four major international societies (European Society of Cardiology, American College of Cardiology, American Heart Association and American Society of Endocrinology) recommend measurement of Lp-PLA2 for risk stratification in asymptomatic adults.
The liquid-stable, enzymatic DiaSys test Lp PLA2 FS, which determines the activity of the enzyme Lp-PLA2 in serum and plasma, has been available for many years. The assay covers a wide measuring range up to 2000 U/L, offers outstanding onboard and calibration stability and shows excellent precision at clinical cut-off levels. No significant interferences are observed by endogenous compounds; frequently used drugs for dyslipidemia and atherosclerosis do not affect the test.
As no reference method or material for Lp-PLA2 has been available, DiaSys applied the scientifically proven traceability to the reagent specific molar extinction coefficient of 4 nitrophenol to their parameter Lp-PLA2 FS. By this proceeding, DiaSys Lp-PLA2 FS is directly traceable to the Lp-PLA2 reaction product 4-nitrophenol.
Read more